Meeting
2017 Genitourinary Cancers Symposium
Impact of cytoreductive nephretomy on timing of systemic therapy in metastatic kidney cancer.
Authors
Liam Connor Macleod
University of Washington, Seattle, WA
Liam Connor Macleod , Atreya Dash , George Schade , Jonathan D. Harper , Daniel W. Lin , Scott S. Tykodi , John L. Gore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 503)
DOI
10.1200/JCO.2017.35.6_suppl.503
Abstract #
503
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Litmus test or destination systemic therapy? Trends in referral for surgery after initial systemic therapy in metastatic kidney cancer.
First Author: Liam Connor Macleod
Poster
2022 ASCO Genitourinary Cancers Symposium
Active surveillance in metastatic renal cell carcinoma: A single-center cohort.
First Author: William Schwartzman
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani